JP2009526750A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009526750A5 JP2009526750A5 JP2008547703A JP2008547703A JP2009526750A5 JP 2009526750 A5 JP2009526750 A5 JP 2009526750A5 JP 2008547703 A JP2008547703 A JP 2008547703A JP 2008547703 A JP2008547703 A JP 2008547703A JP 2009526750 A5 JP2009526750 A5 JP 2009526750A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- glp
- composition
- mimetibody
- animal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 65
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 claims 50
- 108090000765 processed proteins & peptides Proteins 0.000 claims 45
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 44
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 44
- 229920001184 polypeptide Polymers 0.000 claims 39
- 102000004196 processed proteins & peptides Human genes 0.000 claims 39
- 241001465754 Metazoa Species 0.000 claims 34
- 210000000056 organ Anatomy 0.000 claims 33
- 210000001519 tissue Anatomy 0.000 claims 33
- 102000039446 nucleic acids Human genes 0.000 claims 22
- 108020004707 nucleic acids Proteins 0.000 claims 22
- 150000007523 nucleic acids Chemical class 0.000 claims 22
- 108060003951 Immunoglobulin Proteins 0.000 claims 20
- 102000018358 immunoglobulin Human genes 0.000 claims 20
- 239000004480 active ingredient Substances 0.000 claims 19
- 208000008589 Obesity Diseases 0.000 claims 16
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 claims 16
- 235000020824 obesity Nutrition 0.000 claims 16
- 210000004027 cell Anatomy 0.000 claims 15
- 229940079593 drug Drugs 0.000 claims 14
- 239000003814 drug Substances 0.000 claims 14
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 8
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 8
- 208000030159 metabolic disease Diseases 0.000 claims 7
- 150000001413 amino acids Chemical group 0.000 claims 5
- 102000040430 polynucleotide Human genes 0.000 claims 5
- 108091033319 polynucleotide Proteins 0.000 claims 5
- 239000002157 polynucleotide Substances 0.000 claims 5
- 102000004877 Insulin Human genes 0.000 claims 4
- 108090001061 Insulin Proteins 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 4
- 230000000975 bioactive effect Effects 0.000 claims 4
- 229940125396 insulin Drugs 0.000 claims 4
- 230000002950 deficient Effects 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 210000003403 autonomic nervous system Anatomy 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 2
- 241001260012 Bursa Species 0.000 claims 1
- 102000006395 Globulins Human genes 0.000 claims 1
- 108010044091 Globulins Proteins 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 206010020710 Hyperphagia Diseases 0.000 claims 1
- 210000001015 abdomen Anatomy 0.000 claims 1
- 230000002924 anti-infective effect Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000010836 blood and blood product Substances 0.000 claims 1
- 229940125691 blood product Drugs 0.000 claims 1
- 210000000845 cartilage Anatomy 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000003792 electrolyte Substances 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- -1 hormonal drugs Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 230000003914 insulin secretion Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000007914 intraventricular administration Methods 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 claims 1
- 235000020830 overeating Nutrition 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 210000001215 vagina Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75282605P | 2005-12-22 | 2005-12-22 | |
| PCT/US2006/062223 WO2007076319A2 (en) | 2005-12-22 | 2006-12-18 | Human glp-1 mimetibodies and compositions for treating obesity and related disorders, methods and uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009526750A JP2009526750A (ja) | 2009-07-23 |
| JP2009526750A5 true JP2009526750A5 (enExample) | 2009-09-17 |
Family
ID=38218787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008547703A Pending JP2009526750A (ja) | 2005-12-22 | 2006-12-18 | Glp−1アゴニスト、組成物、方法および使用 |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1968645A4 (enExample) |
| JP (1) | JP2009526750A (enExample) |
| CA (1) | CA2634784A1 (enExample) |
| WO (1) | WO2007076319A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200843794A (en) * | 2006-12-21 | 2008-11-16 | Centocor Inc | Use of long-acting GLP-1 receptor agonists to improve insulin sensitivity and lipid profiles |
| CN101918027A (zh) * | 2007-11-02 | 2010-12-15 | 森托科尔奥索生物科技公司 | 半合成GLP-1肽-Fc融合构造、方法及其用途 |
| US8580927B2 (en) | 2008-01-31 | 2013-11-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Engineered antibody constant domain molecules |
| TWI829687B (zh) | 2018-05-07 | 2024-01-21 | 丹麥商諾佛 儂迪克股份有限公司 | 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物 |
| EP3947451A1 (en) | 2019-04-01 | 2022-02-09 | Novo Nordisk A/S | Antibodies directed against liraglutide and use thereof |
| US20230183335A1 (en) | 2020-06-03 | 2023-06-15 | Københavns Universitet | Glp1r agonist nmdar antagonist conjugates |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005231359A1 (en) * | 2004-03-31 | 2005-10-20 | Centocor, Inc. | Human GLP-1 mimetibodies, compositions, methods and uses |
-
2006
- 2006-12-18 CA CA002634784A patent/CA2634784A1/en not_active Abandoned
- 2006-12-18 EP EP06846650A patent/EP1968645A4/en not_active Withdrawn
- 2006-12-18 JP JP2008547703A patent/JP2009526750A/ja active Pending
- 2006-12-18 WO PCT/US2006/062223 patent/WO2007076319A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008525477A5 (enExample) | ||
| US9944687B2 (en) | Compounds and their effects on feeding behaviour | |
| US8450459B2 (en) | IL-21 derivatives and variants | |
| ES2732291T3 (es) | Péptidos terapéuticos | |
| EP1871794B1 (en) | Modified pyy(3-36) peptides and their effects on feeding behavior | |
| US20180280480A1 (en) | Compositions and peptides having dual glp-1r and glp-2r agonist activity | |
| AU2019256245B2 (en) | Acylated GLP-1 derivative | |
| AU2019218147B2 (en) | FGF21 variant, fusion protein and application thereof | |
| EP2025684A1 (en) | Glucagon analogues | |
| KR20070004078A (ko) | 인간 glp-1 모방체, 조성물, 방법 및 용도 | |
| ME02185B (me) | Anti-il-6 antitela, preparati, postupci pripreme i upotrebe | |
| JP2005512522A5 (enExample) | ||
| TW200843794A (en) | Use of long-acting GLP-1 receptor agonists to improve insulin sensitivity and lipid profiles | |
| TW201741333A (zh) | Mic-1化合物及其用途 | |
| CN111163795A (zh) | 用于治疗肥胖症的mic-1和glp-1 | |
| KR101661332B1 (ko) | 글루카곤 유사 펩타이드-1 수용체 항진제를 포함하는 근감소증 치료용 약학 조성물 | |
| JP2009526750A5 (enExample) | ||
| RU2012106302A (ru) | Аналоги инсулиноподобного фактора роста-1 (igf-1), содержащие аминокислотную замену в положении 59 | |
| Mak et al. | Preparation of potent leptin receptor antagonists and their therapeutic use in mouse models of uremic cachexia and kidney fibrosis | |
| JP2021505656A (ja) | グルカゴン様ペプチド | |
| EP3281951A1 (en) | Insulinotropic peptide derivative with modified n-terminal charge | |
| JP2008546373A5 (enExample) | ||
| CN111727198A (zh) | Pyy类似物 | |
| CN118401250A (zh) | 用于治疗肥胖症的il-4衍生肽 | |
| ES2324306T3 (es) | Uso de il-17f para el tratamiento y/o la prevencion de enfermedades neurologicas. |